Articles

Amylin sues Lilly over drug development deal

Amylin Pharmaceuticals Inc. said Monday it filed a lawsuit against Eli Lilly and Co., accusing the larger drugmaker of breaking their commercialization deal for diabetes drugs by teaming with the German company Boehringer Ingelheim to develop and sell a competing product.

Read More

Analysts demand news on next Lilly blockbuster

Eli Lilly and Co. spends a lot of time these days telling the rest of the story—how well it’s doing in areas not connected to highly lucrative drugs about to see their patents expire. But for the most part, investors and analysts just want to know when the next blockbuster will be coming.

Read More

Firm joins race with IU autism drug

The Indiana University School of Medicine has licensed a pediatric psychiatrist’s patent on
an alcohol-dependency drug that the doctor discovered improves the language and social skills of autism patients. IU has licensed the patent to Indianapolis-based Confluence Pharmaceuticals Inc.

Read More

UPDATE: Bioanalytical researcher opening lab in Indianapolis

Advion BioServices is expected to open the lab at Purdue Research Park in Indianapolis in May with 49 employees. Some of the workers may come from Eli Lilly and Co., which is moving its drug-discovery bioanalytical operations to Advion as part of a partnership.

Read More

Eli Lilly neuroscience chief resigns

David Bredt, vice president of neuroscience research, has resigned “to pursue other opportunities,” according to Lilly spokeswoman Judy Kay Moore. Bredt had overseen Lilly’s development of various drugs, including molecules in late-stage human testing to treat Alzheimer’s and depression.

Read More

Lilly looks to double pipeline size again

Indianapolis-based Lilly is developing what it calls “The Mirror Portfolio,” which it expects to grow to 45 to 60 drugs in five years. This month, Lilly announced it had secured venture-capital funding for the first two drugs in this alternative pipeline.

Read More

Recent successes don’t change Lilly’s outlook

Eli Lilly and Co. can be credited with using acquisitions to unclog its product pipeline. It launched two drugs in the past 18 months, won market approval for a third and will likely get nods for two more drugs this year. Trouble is, they all have paltry sales prospects.

Read More